Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
ANALYSIS: Bitcoin's Daily RSI Indicator Signals Clear Bullish Divergence

ANALYSIS: Bitcoin's Daily RSI Indicator Signals Clear Bullish Divergence

Bitget2024/07/07 16:42

At press time, $58,018 was the level at which bitcoin was attracting the most liquidity, according to CoinGlass data, and its price is eroding buying support below $57,000. Additionally, from July 4 to 5, long Bitcoin bursts totaled more than $220 million. Short positions then experienced a blowout over the weekend, with trader Daan Crypto Trades noting that some short positions were closed when Bitcoin reached a localized high of $58,500. Still other analysts are seeing encouraging signals, including bullish divergences, from the Bitcoin Relative Strength Index (RSI) on the daily time frame. Analyst Wolf posted on X: "My initial bearish target was $52,000, but it looks like the bulls may be one step ahead of me. The daily RSI indicator is showing a clear bullish divergence and the expanding wedge pattern is further increasing investor interest."

1
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Saving in the US, paying globally? Industry research warns: Trump’s push to lower drug prices could instead incentivize pharmaceutical companies to raise prices overseas

A study published in The Lancet indicates that Trump's efforts to lower drug prices in the United States may force pharmaceutical companies to raise prices internationally or exit certain markets, potentially leading to a significant reduction in the approximately $11.6 billion saved annually by Medicare.

智通财经2026/09/14 00:46
Saving in the US, paying globally? Industry research warns: Trump’s push to lower drug prices could instead incentivize pharmaceutical companies to raise prices overseas